BRD4 and ovarian carcinoma: In ovarian cancer, each of the three isoforms was decreased in the BRD4 focal deletion tumors, although only the BRD4-L isoform achieved statistical significance (p = 0.037; Wilcoxon rank-sum test; Figure 2D).